- Home
- AMTB vs IMTX Comparison
AMTB vs IMTX Comparison
Compare AMTB & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMTB | IMTX |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMTB | IMTX |
|---|---|---|
| Price | $28.69 | $8.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $23.67 | $19.00 |
| AVG Volume (30 Days) | 436.0K | ★ 475.1K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $7.67 | $25.91 |
| P/E Ratio | $29.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.62 | $5.05 |
| 52 Week High | $30.60 | $12.41 |
Technical Indicators
Market Signals| Indicator | AMTB | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 43.91 |
| Support Level | $21.68 | $8.60 |
| Resistance Level | $30.60 | $10.41 |
| Average True Range (ATR) | 0.63 | 0.42 |
| MACD | -0.25 | -0.05 |
| Stochastic Oscillator | 21.47 | 33.54 |
Price Performance
Historical ComparisonAbout AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.